In Leander's concept, buying a 10% share of $1 million is to prepare for those drugs that have passed the first phase of clinical practice.

The first phase of clinical practice is a safety experiment, which is prepared by testing whether the drug has strong side effects.

It is not difficult to pass this project. If you take a few milligrams a day, Guanyindi can also pass the first phase of clinical testing.

Therefore, if you can actually get a valuation of US$10 million after the first phase of clinical practice, you must be famous and promising.

Just like now, if Yang Rui or his laboratory produces a certain compound and passes the first phase of clinical experiments, he will naturally get a valuation of tens of millions.

However, Yang Rui is now empty-handed.

It means that he used his name to exchange it for a valuation of tens of millions of dollars.

This was US$10 million in 1986, and its value was quite high. Moreover, although the biomedical community was a bit bubble in the 1980s, it could not be compared with the Internet industry. There were only a few pharmaceutical companies that could afford large sums of funds, which were relatively conservative.

The valuation of $15 million offered by Green Stone Corner has even washed away Leander's perception.

If you say that pharmaceutical companies occasionally produce one or two fools, just like real estate developers, they always have their heads twitching and buy a piece of bad land with a sign. However, the probability of two fools meeting together at the same time is relatively small.

Leander looked at the manager of Green Stone Corner on the left, and then the manager of Glenski on the right, and couldn't help but think.

"1.7 million US dollars, 10 percent." Glenski's Thorndike offered another price.

Hawthorne of Green Rock called out $1.8 million and looked at Thorndike.

Leander was familiar with this look, and that was the look that I would withdraw if you shouted high.

Leander's attention was on Thorndike's face.

Thorndike smiled proudly and said steadily: "1.85 million US dollars, 10%."

He didn't have to buy a higher price anymore. When Hawthorne of Green Stone Corner specified to withdraw, he had to save a little for the company.

Hawthorne's expression was a little distorted. He hesitated for several seconds. Before Yang Rui was about to speak, he said: "1.5 million US dollars, 8%."

At first glance, he seemed to have lowered the number, but because the proportion he wanted was smaller, the actual valuation was higher, reaching $18.75 million. Although it was only $250,000 more than Glenske, where Thorndike was located, it made the latter even more confused.

Leander suddenly realized that the two companies were actually competing for the right to participate.

Ten percent or eight percent of the equity is just an entry threshold for them. The real spending of a company is only more than one million US dollars.

Judging from the 1986-year standard, more than one million US dollars is not a huge amount for pharmaceutical companies. Whether it is for marketing or research investment, it is a expense of less than a month.

However, Leander did not obtain the company's relevant authorization, which made him a little anxious.

Fortunately, Yang Rui quickly stopped the circular price quotation between Green Stone Corner and Glenski, waved his hand and said, "There is one thing you may not be clear about. The new medicine I made will be put into production in China."

"Huh? Is it produced in China?" Thorndike sat upright.

Hawthorne and Leander also showed attention. However, compared to Glenski, Green Stone Corner and Carliss Pharmaceutical are both small and medium-sized enterprises, and they do not have such high requirements for the source of the drugs.

Glenski cannot do it. They are world-class multinational companies, with drugs produced in the United States and drugs produced in China, and there are still some differences in sales.

Of course, it is not completely impossible. For example, India has produced various drugs for European and American pharmaceutical companies for a long time, and its chemical industry was once quite prosperous.

Yang Rui no matter what the several companies thought, he smiled and said, "I have two suggestions. One is to build a joint venture factory and everyone can share the benefits of the production part. If you don't want to, you can also act as a sales agent, but this priority must be lower than that of the partners of the joint venture factory. Only when the joint venture party gives up the sales will it be handed over to other companies."

Several white men looked at each other again.

"Professor Yang, Gaucher's disease is a rare disease, and there are only hundreds of thousands of patients around the world. If you establish a joint venture, the profit in production will be very low." Hawthorne and the white man who came with him took a few seconds and asked again.

"No." Yang Rui said: "We have new ideas about enzyme replacement. If it can be realized, it will require a larger factory to accommodate it. Therefore, production costs and production profits will be higher than ordinary drugs."

"Don't you use extracts from the human placenta?" The white male behind Hawthorne suddenly asked.

"No." Yang Rui simply answered. As a rare disease, Gaucher disease has been studied in the medical field for a lot of research, which is also one of the reasons why Yang Rui chose it. If there is no research from his previous generations for more than 20 years, you have to do basic research by yourself. This is not a simple task, especially the requirements of modern medicine, which must be quantitative results. It is difficult to recognize a plan or direction given for granted for granted, and quantitative often means long-term experiments and is not easy.

In the early research on Gaucher's disease, enzyme replacement is the most natural way of thinking.

The structure of gluceta cerebrosidase in patients with Gaucher disease has changed and cannot play its due role. So, supplementing with some normal gluceta cerebrosidases will be better.

If the enzyme lacks is a common variety, this solution will initially solve Gaucher disease. Unfortunately, the medical experts who studied Gaucher disease in the early stages were unable to find a more accessible source of glucetosides.

In fact, most of the compounds synthesized in the human body are difficult to have a stable supply. For example, the insulin needed by diabetics has been found to be cheap, stable and large-scale supply after many generations of research.

Since there is no ready-made supply of glucetalyticase, it can only be found in the human body and searched for it. In the end, only the human placenta is a very reluctant source of supply. After all, it is abandoned. Although there are many troubles in collection and use, it is always a life-saving thing.

However, it can be imagined that when using this extraction method, the cost of glucetalyses is extremely high, and there are very few Gaucher patients who can be treated.

Yang Rui's alternative solution is to prepare glucetosidase analogs in ovarian cells of Chinese hamsters through DNA recombination technology. Although it cannot completely cure Gaucher's disease, the biweekly solution can greatly prolong the patient's lifespan and reduce pain.

For hundreds of thousands of people suffering from Gaucher disease and those with Gaucher disease who will continue to appear in the future, this is the sound of heaven.

"Is there any other way to extract the extract from the human placenta? Is there an experimental plan?" Glenshik's man continued to ask.

Yang Rui smiled and refused to talk about DNA recombination technology. He didn't have to explain the drug development plan to several representatives of pharmaceutical companies, but his confidence and the halo of the Nobel Prize enveloped the entire laboratory.

"In principle, we are willing to participate in the joint venture." It was still Glenski's people who spoke first.

"We need to think about it." Hawthorne's voice was a little low. Green Stone Corner had never thought of the joint venture before.

Leander hesitated for a moment and could only say regretfully: "Let's withdraw."

Carliss is the only one who only has the sales and production department and relies on purchasing various formulas to survive. They do not have the ability and ambition to cross-border joint ventures.

Yang Rui expressed satisfaction. From his perspective, as long as he could motivate a foreign company, it would mean that the plan was effective and then the plan was made. As for how to achieve it, it was the job of Secretary Hu and his office.

What Yang Rui really cares about is the technology of DNA recombination. Although recombinant DNA has been ruined by various laboratories in more than ten or twenty years, recombinant DNA is still very high-end when the human genome project has not been completed or even been actually carried out.

It is a good thing that can be realized and promoted into practice for the ion channel laboratory to be famous and wealthy.
Chapter completed!